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External validationa b s t r a c t
Background and purpose: We externally validated a previously established multivariable normal-tissue
complication probability (NTCP) model for Grade 2 acute esophageal toxicity (AET) after intensity-
modulated (chemo-)radiotherapy or volumetric-modulated arc therapy for locally advanced non-small
cell lung cancer.
Materials and methods: A total of 603 patients from five cohorts (A–E) within four different Dutch insti-
tutes were included. Using the NTCP model, containing predictors concurrent chemoradiotherapy, mean
esophageal dose, gender and clinical tumor stage, the risk of Grade 2 AET was estimated per patient and
model discrimination and (re)calibration performance were evaluated.
Results: Four validation cohorts (A, B, D, E) experienced higher incidence of Grade 2 AET compared to
the training cohort (49.3–70.2% vs 35.6%; borderline significant for one cohort, highly significant for three
cohorts). Cohort C experienced lower Grade 2 AET incidence (21.7%, p < 0.001). For three cohorts (A–C),
discriminative performance was similar to the training cohort (area under the curve (AUC) 0.81–0.89 vs
0.84). In the two remaining cohorts (D–E) the model showed poor discriminative power (AUC 0.64 and
0.63). Reasonable calibration performance was observed in two cohorts (A–B), and recalibration further
improved performance in all three cohorts with good discrimination (A–C). Recalibration for the two
poorly discriminating cohorts (D–E) did not improve performance.
Conclusions: The NTCP model for AET prediction was successfully validated in three out of five patient
cohorts (AUC 0.80). The model did not perform well in two cohorts, which included patients receiving
substantially different treatment. Before applying the model in clinical practice, validation of discrimina-
tion and (re)calibration performance in a local cohort is recommended.
 2018 Elsevier B.V. All rights reserved. Radiotherapy and Oncology 129 (2018) 249–256Acute esophageal toxicity (AET) is frequently observed in locally
advanced non-small cell lung cancer (LA-NSCLC) patients undergo-
ing (chemo-)radiotherapy, particularly when patients receive
concurrent chemotherapy [1,2]. Normal-tissue complicationprobability (NTCP) models can help to estimate the risk of moder-
ate or severe AET, which may be of benefit for anticipating events
of hospitalization or treatment interruptions due to AET [3–7].
These multivariable NTCP models may also be used by doctors as
a tool to support their decision on whether or not to treat at the
cost of more AET [8–10]. Furthermore, in case there is an increased
risk of AET, patients may be selected that benefit most from other
radiotherapy techniques such as proton therapy [11,12].
250 External validation of an NTCP model for acute esophagitisThe vast majority of the reported NTCP models for AET are
based on 3-dimensional conformal radiotherapy (3D-CRT)
techniques. Intensity-modulated radiation therapy (IMRT) and
volumetric-modulated arc therapy (VMAT), however, produce
more conformal dose distributions at the cost of increased volumes
receiving lower dose [13–16]. These differences may result in a dif-
ferent toxicity profile and thus require new NTCP models [17–19].
Therefore, the available NTCP models based on 3D-CRT may not be
appropriate for AET risk prediction in patients treated with modern
dose delivery techniques. We previously reported on an IMRT- and
VMAT-based multivariable NTCP model for Grade 2 AET [20].
This model was internally validated and the area under the recei-
ver operating curve (AUC) was 0.84 (0.82 after correction for opti-
mism) indicating good discriminative power of the model.
Nonetheless, as reproducibility (model performance on new sam-
ples from the same target population), and transportability (model
performance on samples from different but related populations) of
well internally validated prediction models can still be poor, exter-
nal validation is needed to assess ‘generalizability’ of the NTCP
model to external patient cohorts [21–24].
In this study, we used five patient cohorts from four different
Dutch institutes to externally validate the previously reported
multivariable NTCP model for Grade 2 AET after IMRT or VMAT
for LA-NSCLC (TRIPOD statement Type 4 external validation study
[24]).Materials and methods
Established NTCP model for AET
The model was developed using a training cohort of 149 LA-
NSCLC patients who underwent (chemo-)radiotherapy using IMRT
or VMAT at the Radboud University Medical Center (Nijmegen, The
Netherlands) between March 2008 and June 2013. Information on
treatment and patient selection has been previously described in
more detail [20]. In brief, all patients received 60 Gy (median
66 Gy) in 2 Gy fractions (once daily), with or without (concurrent
or sequential) chemotherapy (Table 1). The sequential chemother-
apy regimen typically consisted of 3 (3-weekly) courses of
gemcitabine/cisplatin, whereas all patients undergoing concurrent
chemoradiotherapy (CCR) received 2 (3-weekly) courses of
etoposide/cisplatin.
AET was scored weekly during treatment by the treating radia-
tion oncologist using the Radiation Therapy Oncology Group
(RTOG) acute radiation morbidity scoring criteria [25]. Toxicity
scoring was continued after treatment until acute toxicity resolved.
The AET scores were analyzed in relation to clinical risk factors and
radiation treatment plan derived dose volume histogram (DVH)
parameters.
After multivariable logistic regression, with bootstrap sampling
for model order and predictor selection, the following optimal
NTCP model for Grade 2 AET (maximum at any timepoint) was
established:
NTCP x
 
¼ 1
1þ eS x
  ð1Þ
with,
S x
 
¼ 6:418þ 2:645  CCRþ 0:117 MEDþ 1:204  Gender
þ 0:994  cT ð2Þ
and CCR = concurrent chemoradiotherapy (1 = yes, 0 = no),
MED = mean esophageal dose (preferably first converting physical
dose to linear-quadratic equivalent dose in 2 Gy fractions witha/b = 10 Gy using MED and its standard deviation [8,26], or
esophageal DVH or full dose matrix [27,28]), gender (1 = female,
0 = male) and cT = clinical tumor stage (0 < cT3, 1  cT3).External validation cohorts
Five cohorts from four different Dutch institutes were available
for validation of the abovementioned NTCP model. The patient,
tumor and treatment characteristics of each cohort are listed in
Table 1 and Supplementary Material Table S1. Except for cohorts
D and E, acute toxicity was retrieved retrospectively for these
cohorts from the electronic health records. For all cohorts toxicity
was scored weekly during radiotherapy and continued after radio-
therapy until toxicity resolved, maximum AET score was used as
outcome for model performance evaluation.
Cohort A (n = 47) was also treated in the Department of Radia-
tion Oncology of the Radboud University Medical Center [20]. This
cohort consisted solely of stage III NSCLC patients that were treated
with (chemo-)radiotherapy using VMAT between June 2013 and
December 2014. Radiotherapy and chemotherapy regimens and
AET scoring were similar to those of the training cohort. Cohort B
(n = 73) consisted of stage III NSCLC patients which received
(chemo-)radiotherapy at ‘Radiotherapiegroep’ (Arnhem, The
Netherlands) between January 2014 and March 2016 using mostly
VMAT. The radiotherapy regimen and AET scoring were similar to
the training cohort. Sequential chemotherapy was platinum based,
preferentially cisplatin. Concurrent chemotherapy consisted of 2
courses of platinum/etoposide sometimes preceded by one course
of a platinum doublet with either etoposide, or pemetrexed.
Cohort C consisted of 156 stage I-III NSCLC patients treated with
(chemo-)radiotherapy at The Netherlands Cancer Institute
(Amsterdam, The Netherlands) between December 1998 and
March 2003 using 3D-CRT [29]. For 27 patients, however, the
predictor ‘clinical T-stage’ required in the NTCP-model was not
available and therefore 129 patients with complete data were
included. Varying radiotherapy schedules (total dose 49.5–94.5 Gy,
2.25–2.75 Gy per fraction) were administered, and sequential and
concurrent chemotherapy consisted of 2 courses of gemcitabine/
cisplatin or daily low-dose cisplatin, respectively. The incidence
of AET in this cohort has been evaluated and reported previously;
AET was scored using the RTOG scoring criteria [29]. Cohort D was
also retrieved from The Netherlands Cancer Institute comprising
172 patients treated between January 2008 and November 2010,
and their AET was scored using the Common Toxicity Criteria
Adverse Effects (CTCAE) v3.0 [30]. See Table S2 in the Supplemen-
tary Material for a comparison between AET scoring using RTOG,
CTCAE v3.0 and v4.0. These patients all underwent concurrent
chemoradiotherapy (daily low-dose cisplatin) using IMRT (66 Gy
in 24 fractions) [31].
The patients from cohort E (n = 398) were treated at MAASTRO
Clinic (Maastricht, The Netherlands) between April 2006 and
October 2013. Of these, 216 patients had missing data, i.e., missing
mean esophageal dose (n = 201, for technical reasons), AET score
(n = 4; CTCAE v3.0 and v4.0 [32]), chemotherapy sequence (n = 1)
and clinical T-stage (n = 10), and thus 182 patients were included.
Patients received 1–3 courses of induction chemotherapy
(gemcitabine or cisplatinum) typically followed by concurrent
chemotherapy (n = 156) or sequential chemotherapy (n = 24)
consisting of 2 courses of a platinum-based doublet. Two
patients received no chemotherapy at all. The majority of patients
(n = 161) received a total radiation dose of 69 Gy in 1.5 Gy fractions
twice daily up to 45 Gy, followed by 8 to 24 Gy in 2 Gy once daily
fractions, depending on the dose to the organs at risk (OAR) [33].
Eighteen patients were treated within the FDG-PET-based interna-
tional multicenter Phase II dose escalation trial ‘‘PET-boost” [34];
they received 66 Gy in 24 once daily fractions to the gross tumor
Table 1
Comparison of validation cohort characteristics with the training cohort for the NTCP model predictors and AET.
NTCP model predictors Training cohort Validation cohorts
A B C D E A–Ey
n = 149 n = 47 p n = 73 p n = 129 p n = 172 p n = 182 p n = 603 p
Gender (%)
Male 97 (65.1) 18 (38.3) 38 (52.1) 88 (68.2) 102 (59.3) 113 (62.1) 359 (59.5)
Female 52 (34.9) 29 (61.7) 0.002 35 (47.9) 0.08 41 (31.8) 0.61 70 (40.7) 0.30 69 (37.9) 0.65 244 (40.5) 0.65
T-stage (%)
2 75 (50.3) 21 (44.7) 24 (32.9) 62 (48.1) 91 (52.9) 78 (42.9) 276 (45.8)
3 74 (49.7) 26 (55.3) 0.51 49 (67.1) 0.02 67 (51.9) 0.72 81 (47.1) 0.66 104 (57.1) 0.19 327 (54.2) 0.19
Chemotherapy (%)
Concurrent 93 (62.4) 33 (70.2) 45 (61.6) 25 (19.4) 172 (100.0) 156 (85.7) 431 (71.5)
Sequential/none 46/10 (37.6) 12/2 (29.8) 0.38 24/4 (38.4) 1.00 31/73 (80.6) <0.001 – <0.001 24/2 (14.3) <0.001 91/81 (28.5) <0.001
Dmean esophagus in Gy
Median physical dose (IQR) 25.2 28.8 26.5 – – 20.0 25.5
(20.5–31.0) (22.2–34.1) 0.06 (23.3–32.7) 0.16 – – (14.9–27.9) <0.001 (17.5–32.7) 0.72
Median EQD2a/b=10 (IQR) 24.0 – – 24.1 30.1 – –
(19.6–30.1) – – (10.6–33.3) 0.20 (23.7–36.5) <0.001 – –
Grade 2 AET
RTOG 53 (35.6) 33 (70.2) <0.001 36 (49.3) 0.06 28 (21.7) 0.01 – – 323 (53.6) <0.001
CTCAE* – – 62 (84.9) <0.001 – 102 (59.3) <0.001 124 (68.1) <0.001 –
Grade 3 AET
RTOG 13 (8.7) 10 (21.3) 0.03 12 (16.4) 0.11 7 (5.4) 0.36 – – 124 (20.6) <0.001
CTCAE* – – 13 (17.8) 0.07 – 40 (23.3) <0.001 55 (30.2) <0.001 –
Abbreviations: NTCP = normal-tissue complication probability; AET = acute esophageal toxicity; Dmean = mean dose; IQR = interquartile range; EQD210 = equivalent dose in 2 Gy fractions with a/b = 10 Gy; RTOG = Radiation Therapy
Oncology Group; CTCAE = Common Toxicity Criteria Adverse Effects; N/A = not applicable.
The p-values are calculated for the comparison between the validation cohort and the training cohort (Mann–Whitney-U or Fisher’s exact test where appropriate). Bold p-values are statistically significant. *p-values of AET scoring
using CTCAE are calculated with respect to the training cohort AET scoring that used RTOG.
y The combined cohort A-E has a mixture of physical and equivalent mean easophageal dose, and a mixture of RTOG and CTCAE-based toxicity scores.
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252 External validation of an NTCP model for acute esophagitisvolume (GTV). In case dose escalation was possible (by increasing
the fraction dose with equal number of fractions), an integrated
boost was delivered to the primary tumor as a whole or to the vol-
ume of the primary tumor encompassed by 50% of the maximum
standardized uptake value of FDG.Statistical analysis
Differences between the training cohort from which the NTCP
model was developed and the validation cohorts were tested for
statistical significance using the Mann–Whitney–U or Fisher’s
exact test, where appropriate (SPSS software, version 22.0; SPSS
Inc., Chicago, USA). A p-value of <0.05 was considered statistically
significant.Model performance
The risk of Grade 2 AET was calculated for each individual
patient by applying the original NTCP model (Formula 1 and 2).
The discriminative power of the model for the validation cohorts
was assessed by calculating the area under the curve (AUC) of
the receiver operating characteristic (ROC). The criterion for suc-
cessful external validation was AUC 0.80, i.e., no significant dete-
rioration of model performance with respect to the training cohort
(AUC 0.84, or 0.82 after optimism correction [20]). Furthermore,
the discrimination slopes were calculated by the absolute differ-
ence between the mean predicted risk of the groups with and with-
out Grade 2 AET.
Model calibration performance was assessed by calibration
plots displaying grouped observed frequencies versus predicted
outcome [35]. A loess smoother was plotted, which approximates
the y = x identity line in case of good calibration [36]. The 95% con-
fidence intervals of the binomially distributed grouped frequencies
were calculated according to the Wilson interval [37]. Double his-
tograms of predicted probabilities for patients with and without
Grade 2 AET were also generated for the calibration plots.
To assess possible miscalibration in the cohorts, the method of
logistic recalibration was applied [38,39]. The linear predictors for
each patient, i.e., the calculated results after inserting patient
specific parameters into Formula 2, were used as a single predictor
in a new logistic regression model according to:
NTCP x
 
¼ 1
1þ eS
0 x
  ð3Þ
with updated linear predictor
S0 x
 
¼ aþ b  S x
 
ð4ÞTable 2
Performance of the NTCP model after recalibration for the different patient cohorts.
Performance measure Training cohort Validation cohort
A B
n = 149 n = 47 n = 73
Pseudo R2s
Brierscaled 0.35 0.44 0.31
Nagelkerke 0.41 0.55 0.38
Discrimination
AUC (95% CI) 0.84 (0.77–0.91) 0.89 (0.80–0.98) 0.81 (0.70–0.9
SE 0.04 0.05 0.05
Discrimination slope 0.33 0.45 0.30
Calibration
Calibration-in-the-large 0.00 1.18 0.20
Calibration slope 1.00 1.36 0.71
Abbreviations: NTCP = normal-tissue complication probability; AUC = area under the curThe resulting calibration intercept a (‘calibration-in-the-large’)
compares the mean of the predicted risks with the mean of the
observed risk and gives an indication whether predictions are sys-
tematically under- (a > 0) or overestimated (a < 0). The calibration
slope b indicates the level of overfitting (b < 1), i.e., the predictions
are too extreme, or underfitting (b > 1), the predictions are too
mild. Recalibration does neither affect sensitivity nor specificity
and thus ROC and AUC both remain the same [21,35].
The overall performance of the recalibrated models in each
cohort was additionally assessed by calculation of the scaled Brier
score, a quadratic scoring rule corrected for dependence on the
incidence of the outcome [21]. Additionally, Nagelkerke’s R2 was
calculated, which is a logarithmic scoring rule to express the
amount of variance in the dependent variables explained by the
model [39,40].Results
Comparison of cohorts
A comparison of training and validation cohort characteristics
for the NTCP model predictors and AET is listed in Table 1. The inci-
dence of Grade 2 AET in cohorts A, D and E was (nearly) twice the
incidence of Grade 2 AET in the training cohort (70.2%, 59.3% and
68.1% vs 35.6%, respectively; p < 0.001). The patients in cohort C
experienced lower rates of Grade 2 AET compared to the training
cohort (21.7% vs 35.6%, respectively; p = 0.01). Other patient, tumor
and treatment characteristics of the cohorts are listed as Supple-
mentary Material in Table S1.Model performance
A summary of model performance in the validation cohorts, i.e.,
overall performance, discrimination and (re)calibration, is listed in
Table 2. Unsurprisingly, the best performance, as indicated by the
highest value of the scaled Brier and Nagelkerke R2, was seen in
the training cohort. The overall performance was high for cohorts
A, B and C, but was poor for cohorts D and E.
The ROC curves for all cohorts are displayed in Fig. 1. High dis-
criminative performance of similar quality to the training cohort
was obtained for cohorts A, B and C, as indicated by high AUCs
(0.89, 0.81 and 0.84, respectively). Poor discrimination of the
model was found in cohorts D and E (AUC 0.64 and 0.63 respec-
tively). This poor discrimination performance is also demonstrated
by the calculated discrimination slopes (Table 2).
Model calibration performance, without recalibration, can be
visually assessed from the calibration plots shown in Fig. S1 of
the Supplementary Material. Reasonable performance withoutC D E A–E
n = 129 n = 172 n = 182 n = 603
0.24 0.06 0.05 0.19
0.36 0.08 0.06 0.24
1) 0.84 (0.75–0.94) 0.64 (0.55–0.72) 0.63 (0.55–0.71) 0.74 (0.70–0.78)
0.05 0.04 0.04 0.02
0.25 0.06 0.05 0.19
0.15 0.22 1.63 0.57
0.60 0.40 0.29 0.50
ve; CI = confidence interval; SE = standard error.
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T
Fig. 1. ROC curves of the previously published NTCP model [20] applied on all
patient cohorts showing good discriminating performance for 3 out of 5 validation
cohorts as indicated by AUC values (>0.80). Abbreviations: ROC = receiver operating
characteristic; NTCP = normal-tissue complication probability; AUC = area under
the curve.
F.J.W.M. Dankers et al. / Radiotherapy and Oncology 129 (2018) 249–256 253recalibration was found for the model in cohorts A and B, demon-
strated by the loess smoother which was relatively close to the
identity line. The model generally underestimated the risk of Grade
2 AET. Increasingly poor calibration was observed for cohorts C, D
and E.
Calibration plots generated after recalibration are shown in
Fig. 2, and the values for the calibration-in-the-large and calibra-
tion slope are listed in Table 2. For cohorts A and B, good calibra-
tion was achieved after recalibration. Similarly, for cohort C
recalibration moderately improved the agreement between pre-
dicted and observed risk. For cohorts D and E, calibration did not
improve after recalibration, indicated by the limited range of pre-
dicted probabilities (see Fig. 2).Discussion
Recently, we established a multivariable NTCP model for AET in
LA-NSCLC undergoing IMRT or VMAT and after thorough internal
validation the model proved to be robust [20]. However, it is of
paramount importance to perform external validation in order to
ensure that the model is transportable to other patient cohorts
[21,23]. This means that the model produces accurate predictions
in a sample that was drawn from a different but plausibly related
population. Several components of ‘transportability’ can be distin-
guished, such as historical (e.g., a different time period), geograph-
ical (e.g., treated in a different hospital) and methodological (e.g.,
differences in toxicity scoring) transportability [41]. To account
for all these components of transportability, we externally vali-
dated our previously established NTCP model for Grade 2 AET
in cohorts of (LA-)NSCLC patients that were treated by (chemo-)
radiotherapy in different hospitals (cohorts B-E), receiving differ-
ent radiation fractionation schedules (cohorts C-E) and in a histor-
ically different period of time with less conformal dose delivery
techniques (cohort C). Ideally, an NTCP model performs well in
every patient cohort external to the cohort the model was devel-
oped on. However, this so-called ‘strong calibration’ is only consid-ered possible in utopia [35]. Therefore, applying an established
NTCP model in different patient cohorts often needs some form
of adjustments to account for local circumstances [42,43].
Recalibration is a controlled form of model updating; i.e., the
coefficients of the model are adjusted to correct for differences in
for instance event rates. Initial calibration of the model in cohorts
A and B was moderate (see Fig. S1 in the Supplementary Material).
Underestimation of Grade 2 AET was seen, which is possibly due
to a lower incidence of Grade 2 AET in the training cohort (35.6%)
compared to cohort A (70.2%) and cohort B (49.3%). The class
imbalance in the training cohort can affect the estimate of the
model intercept and skews the predicted probabilities. After recal-
ibration of the NTCP model for cohorts A and B, calibration
improved (see Fig. 2). Discrimination of the model was good for
the patients in cohorts A and B (AUC 0.89 and 0.81, respectively).
Formerly, we hypothesized that differences in dose delivery tech-
niques influenced NTCP modeling since the models based on 3D-
CRT did not perform well in head and neck cancer patients who
underwent IMRT [18,20,44,45]. Although cohort C differs substan-
tially from the training cohort regarding treatment technique (3D-
CRT vs IMRT/VMAT), radiation dose (49.5–94.5 Gy vs 66 Gy), the
application of concurrent chemotherapy, and the time period
(1998–2003 vs 2008–2010), the current model performed surpris-
ingly well for this population (AUC 0.84 with a moderately good
recalibration curve). Cohorts D and E showed poor discrimination
(AUC 0.64 and 0.63 respectively) and (re)calibration (see Fig. 1
and Supplementary Material Fig. S1). Re-estimating the regression
coefficients or adding additional predictors that are known for
their association with AET (for example, overall treatment time
(OTT) and chemotherapy regimen; see below) are approaches to
improve model predictions. Besides this, there may be several
other reasons for the poor model performance in these cohorts.
Firstly, the NTCP model was developed using the RTOG grading
scale for AET. However, toxicity for the patients in cohorts D and
E was scored using the CTCAE grading scales for AET. Differences
between scoring systems were reported to be of importance in
modeling of toxicity, for instance for modeling the risk of
radiation-induced pneumonitis [46]. It is likely that such differ-
ences in grading scales affect AET modeling as well. This was illus-
trated for the patients of cohort B for whom both the RTOG and
CTCAE v4.0 grading of AET were available. Applying the NTCP
model using the CTCAE-based AET scores resulted in a high dis-
crimination with AUC of 0.80 (compared to 0.81 for the RTOG
based scores), however, model calibration was poor since it consid-
erably underestimated the risk of CTCAE Grade 2 AET (data not
shown). The latter can be explained by the finding that in 35.6%
of the patients AET was scored as Grade 1 using the RTOG scale
and as Grade 2 using the CTCAE scale (see Table S2 in the Supple-
mentary Material). Secondly, the patients from cohort D received
concurrent chemoradiotherapy in a fundamentally different proto-
col compared to the patients in the training cohort as they received
daily low-dose cisplatin and moderately hypofractionated radio-
therapy schedules. Thirdly, the OTT is shorter for cohorts D and E
(5 weeks) than for the training cohort (6.5 weeks). Besides, the
majority of patients (88.5%) from cohort E were treated twice-
daily. Both factors are known to result in a strong increase of
AET [3,6]; including OTT in the NTCP model for patients receiving
treatment with a shorter OTT is likely to improve model perfor-
mance for these cohorts as reported by Dehing-Oberije et al. [3].
Despite our aim to thoroughly validate the established NTCP
model for Grade 2 AET by assessing the transportability of the
model using multiple different patient cohorts, some potential lim-
itations should be noted. Firstly, the data of most cohorts were
retrieved retrospectively (except cohorts D and E) possibly intro-
ducing unwanted bias. Furthermore, for some patients of the vali-
dation cohorts the necessary NTCP model predictor values could
Fig. 2. Calibration plots of the NTCP model applied on all validation cohorts separate and combined, after recalibration per cohort. Recalibrated predicted probabilities are
calculated by inserting the cohort-specific calibration-in-the-large and calibration slope values in Formulas 3 and 4. The triangles indicate grouped predicted probabilities of
Grade 2 AET vs grouped observed frequencies. The vertical lines represent 95% confidence intervals. A loess smoother was fitted and displayed by the black line. Perfect
predictions should be close to the dashed 45 reference line. Double histograms of patients with and without Grade 2 AET, binned according to their predicted probabilities,
are displayed at the bottom. Abbreviations: NTCP = normal-tissue complication probability; AET = acute esophageal toxicity; AUC = area under the curve.
254 External validation of an NTCP model for acute esophagitisnot be retrieved resulting in exclusion of these patients. The num-
ber of patients of the separate cohorts may be considered low for
model validation, however, the total number of patients (n = 603)
included in the validation cohorts is substantial. For future work,
by making data ‘smarter’, e.g., by implementing semantic technolo-
gies [47,48], and more easily accessible, by adhering to the FAIRdata principles [49], distributed learning techniques can allow
training and validation of models in much larger cohorts of
patients that were not treated according to any specific study pro-
tocol [50]. Finally, this study is an external validation of a model
previously published by us and we therefore encourage indepen-
dent external validation by other research groups.
F.J.W.M. Dankers et al. / Radiotherapy and Oncology 129 (2018) 249–256 255In conclusion, the established NTCP model for the prediction of
Grade 2 AET in patients treated for locally advanced NSCLC suc-
cessfully validated in 3 out of 5 patient cohorts, but performed
poor in 2 cohorts that were significantly different for many vari-
ables. Before implementing the NTCP model in clinical practice,
one should always check model discrimination and calibration per-
formance in a local cohort representative of the patients for which
the model is intended to be used in the future. If good discrimina-
tion but poor calibration is observed a local recalibration of the
model is advised. After implementation the model should be eval-
uated over time for new patients since treatments and cohorts
change and model performance can deteriorate to the point where
the model coefficients need to be updated or additional predictors
may become relevant and complete remodeling is necessary.Conflict of interests
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